Thank you.
We've talked about pharmacare, and I know you gave us some testimony on that. I won't bother there.
There's a recommendation regarding the government supplying CADTH with additional funding to undertake its capacity to review high-cost specialty drugs and develop expertise to support these negotiations.
What other recommendations would you ask this committee to make to improve access for rare diseases?